ChartRow logo
Share this page

INCY SEC filings (2026)

CIK 879169 · Services-Commercial Physical & Biological Research (SIC 8731) · incorporated in DE · fiscal year ends in December

2,616 filings on EDGAR since 1994 · 35 annual, 94 quarterly, 278 current · financial statements · earnings

Latest 10-K
Feb 10, 2026
fiscal year to Dec 31, 2025
Latest 10-Q
Jul 28, 2026
quarter to Jun 30, 2026
Latest 8-K
Aug 31, 2026
Other events
Last earnings release
Jul 28, 2026
$2.80 vs $1.76 · ▲ 9.3%
Filings on file
2,616
since 1994, 1,713 insider forms

What happened, last 12 months#

Every earnings release with its print, every report with its quarter, the other 8-Ks by the headline of the press release they furnish or by their items, the proxy statements, and each day an insider bought or sold — newest first, each line opening the filing on EDGAR. The index by form and year follows.

October 2026

September 2026

August 2026

July 2026

June 2026

May 2026

April 2026

March 2026

February 2026

January 2026

December 2025

October 2025

Insider transactions#

What officers, directors and 10% holders reported on Forms 4 and 5 over the last 13 months, from the documents themselves: one insider’s trades of one kind on one day are one row, with the shares, the price range and the total as filed. Open-market buys and sells first; awards, exercises, tax withholding, gifts and employee-plan purchases are grouped below them.

Over the last 13 months insiders sold $28.6M in 20 sales and bought nothing on the open market; 121 other transactions (awards, exercises, tax withholding, gifts and plan purchases).

DateInsider
Oct 15, 2026Form 4CAGNONI PABLO JPresident, Global Head of R&DSold · $298K · 2,642 sh · 10b5-1
Sep 15, 2026Form 4CAGNONI PABLO JPresident, Global Head of R&DSold · $2.8M · 23,218 sh · 10b5-1
Aug 19, 2026Form 4CAGNONI PABLO JPresident, Global Head of R&DSold · $1.4M · 10,801 sh · 10b5-1
Aug 12, 2026Form 4CAGNONI PABLO JPresident, Global Head of R&DSold · $1.3M · 10,803 sh · 10b5-1
Aug 5, 2026Form 4CAGNONI PABLO JPresident, Global Head of R&DSold · $1.3M · 10,640 sh · 10b5-1
Aug 5, 2026Form 4Mayes Patrick AEVP & Chief Scientific OfficerSold · $274K · 2,207 sh · 10b5-1
Aug 3, 2026Form 4Mayes Patrick AEVP & Chief Scientific OfficerSold · $729K · 6,055 sh · 10b5-1
Jul 31, 2026Form 4Mayes Patrick AEVP & Chief Scientific OfficerSold · $5.0M · 41,899 sh · 10b5-1
Jul 31, 2026Form 4CAGNONI PABLO JPresident, Global Head of R&DSold · $1.9M · 15,888 sh · 10b5-1
Jul 16, 2026Form 4Stein Steven HCMO & Head of Late-Stage Dev.Sold · $215K · 1,877 sh · 10b5-1
Jul 16, 2026Form 4Issa Mohamed KhairieEVP, Head of U.S. CommercialSold · $126K · 1,093 sh · 10b5-1
Jul 15, 2026Form 4Stein Steven HCMO & Head of Late-Stage Dev.Sold · $3.2M · 28,237 sh · 10b5-1
Jun 4, 2026Form 4Tray ThomasPrincipal Accounting OfficerSold · $264K · 2,639 sh · 10b5-1
May 26, 2026Form 4Tray ThomasPrincipal Accounting OfficerSold · $200K · 2,051 sh · 10b5-1
May 19, 2026Form 4Clancy Paul JDirectorSold · $1.4M · 15,000 sh · 10b5-1
Apr 17, 2026Form 4CAGNONI PABLO JPresident, Global Head of R&DSold · $1.8M · 18,667 sh · 10b5-1
Mar 17, 2026Form 4CAGNONI PABLO JPresident, R&DSold · $1.8M · 18,667 sh · 10b5-1
Feb 19, 2026Form 4CAGNONI PABLO JPresident, R&DSold · $1.9M · 18,668 sh · 10b5-1
Jan 7, 2026Form 4Issa Mohamed KhairieEVP, Head of US OncologySold · $1.2M · 10,856 sh · 10b5-1
Jan 5, 2026Form 4Stein Steven HEVP & Chief Medical OfficerSold · $1.6M · 15,634 sh · 10b5-1
Awards, exercises, withholding and plan purchases · 121 transactions
DateInsider
Oct 15, 2026Form 4CAGNONI PABLO JPresident, Global Head of R&DExercise or conversion · $174K · 2,642 sh · 10b5-1
Oct 15, 2026Form 4CAGNONI PABLO JPresident, Global Head of R&DExercise or conversion · Employee Stock Option (rig… · $0 · 2,642 sh · 10b5-1
Oct 1, 2026Form 4Heeson LeeEVP, Head of Incyte IntlTax withholding · $54K · 463 sh
Sep 30, 2026Form 4HARRIGAN EDMUNDDirectorAward · $25K · 206 sh
Sep 30, 2026Form 4Clancy Paul JDirectorAward · $25K · 203 sh
Sep 30, 2026Form 4BAKER BROS. ADVISORS LP, 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN6 filersAward · $0 · 644 sh
Sep 22, 2026Form 4Gardner David HEVP, Chief Strategy OfficerTax withholding · $117K · 920 sh
Sep 15, 2026Form 4CAGNONI PABLO JPresident, Global Head of R&DExercise or conversion · $1.5M · 23,218 sh · 10b5-1
Sep 15, 2026Form 4CAGNONI PABLO JPresident, Global Head of R&DExercise or conversion · Employee Stock Option (rig… · $0 · 23,218 sh · 10b5-1
Aug 25, 2026Form 4Basi Ramitpal KEVP, Human ResourcesTax withholding · $65K · 504 sh
Aug 5, 2026Form 4Mayes Patrick AEVP & Chief Scientific OfficerExercise or conversion · $235K · 2,207 sh · 10b5-1
Aug 5, 2026Form 4Mayes Patrick AEVP & Chief Scientific OfficerExercise or conversion · Employee Stock Option (rig… · $0 · 2,207 sh · 10b5-1
Aug 3, 2026Form 4Mayes Patrick AEVP & Chief Scientific OfficerExercise or conversion · $638K · 6,055 sh · 10b5-1
Aug 3, 2026Form 4Mayes Patrick AEVP & Chief Scientific OfficerExercise or conversion · Employee Stock Option (rig… · $0 · 6,055 sh · 10b5-1
Jul 31, 2026Form 4Mayes Patrick AEVP & Chief Scientific OfficerExercise or conversion · $3.0M · 39,712 sh · 10b5-1
Jul 31, 2026Form 4Mayes Patrick AEVP & Chief Scientific OfficerExercise or conversion · Employee Stock Option (rig… · $0 · 39,712 sh · 10b5-1
Jul 23, 2026Form 4Heeson LeeEVP, Head of Incyte IntlAward · Employee Stock Option (rig… · $0 · 15,423 sh
Jul 23, 2026Form 4Heeson LeeEVP, Head of Incyte IntlAward · $0 · 13,498 sh
Jul 23, 2026Form 4Morrissey Michael JamesEVP, Head of Tech. OperationsAward · $0 · 8,999 sh
Jul 23, 2026Form 4Morrissey Michael JamesEVP, Head of Tech. OperationsAward · Employee Stock Option (rig… · $0 · 6,426 sh
Jul 16, 2026Form 4Meury WilliamChief Executive Officer · DirectorAward · $0 · 80,421 sh
Jul 16, 2026Form 4Meury WilliamChief Executive Officer · DirectorAward · Employee Stock Option (rig… · $0 · 77,148 sh
Jul 16, 2026Form 4CAGNONI PABLO JPresident, Global Head of R&DAward · Employee Stock Option (rig… · $0 · 57,861 sh
Jul 16, 2026Form 4Stein Steven HCMO & Head of Late-Stage Dev.Award · Employee Stock Option (rig… · $0 · 42,298 sh · 10b5-1
Jul 16, 2026Form 4Issa Mohamed KhairieEVP, Head of U.S. CommercialAward · Employee Stock Option (rig… · $0 · 33,918 sh · 10b5-1
Jul 16, 2026Form 4CAGNONI PABLO JPresident, Global Head of R&DAward · $0 · 33,508 sh
Jul 16, 2026Form 4Gardner David HEVP, Chief Strategy OfficerAward · Employee Stock Option (rig… · $0 · 31,923 sh
Jul 16, 2026Form 4Hoffman Richard A.EVP & General CounselAward · Employee Stock Option (rig… · $0 · 31,923 sh
Jul 16, 2026Form 4Meury WilliamChief Executive Officer · DirectorAward · $0 · 26,807 sh
Jul 16, 2026Form 4Mayes Patrick AEVP & Chief Scientific OfficerAward · Employee Stock Option (rig… · $0 · 25,538 sh
Jul 16, 2026Form 4Stein Steven HCMO & Head of Late-Stage Dev.Award · $0 · 24,496 sh · 10b5-1
Jul 16, 2026Form 4Basi Ramitpal KEVP, Human ResourcesAward · Employee Stock Option (rig… · $0 · 21,548 sh
Jul 16, 2026Form 4Issa Mohamed KhairieEVP, Head of U.S. CommercialAward · $0 · 19,643 sh · 10b5-1
Jul 16, 2026Form 4Gardner David HEVP, Chief Strategy OfficerAward · $0 · 18,487 sh
Jul 16, 2026Form 4Hoffman Richard A.EVP & General CounselAward · $0 · 18,487 sh
Jul 16, 2026Form 4Mayes Patrick AEVP & Chief Scientific OfficerAward · $0 · 14,790 sh
Jul 16, 2026Form 4CAGNONI PABLO JPresident, Global Head of R&DAward · $0 · 13,403 sh
Jul 16, 2026Form 4Basi Ramitpal KEVP, Human ResourcesAward · $0 · 12,479 sh
Jul 16, 2026Form 4Stein Steven HCMO & Head of Late-Stage Dev.Award · $0 · 9,798 sh · 10b5-1
Jul 16, 2026Form 4Issa Mohamed KhairieEVP, Head of U.S. CommercialAward · $0 · 7,857 sh · 10b5-1
Jul 16, 2026Form 4Gardner David HEVP, Chief Strategy OfficerAward · $0 · 7,395 sh
Jul 16, 2026Form 4Hoffman Richard A.EVP & General CounselAward · $0 · 7,395 sh
Jul 16, 2026Form 4Mayes Patrick AEVP & Chief Scientific OfficerAward · $0 · 5,916 sh
Jul 16, 2026Form 4Basi Ramitpal KEVP, Human ResourcesAward · $0 · 4,991 sh
Jul 16, 2026Form 4Tray ThomasPrincipal Accounting OfficerAward · Employee Stock Option (rig… · $0 · 4,079 sh
Jul 16, 2026Form 4Tray ThomasPrincipal Accounting OfficerAward · $0 · 2,834 sh
Jul 15, 2026Form 4CAGNONI PABLO JPresident, Global Head of R&DTax withholding · $570K · 4,950 sh
Jul 15, 2026Form 4Stein Steven HCMO & Head of Late-Stage Dev.Tax withholding · $355K · 3,088 sh · 10b5-1
Jul 15, 2026Form 4Mayes Patrick AEVP & Chief Scientific OfficerTax withholding · $174K · 1,512 sh
Jul 15, 2026Form 4Issa Mohamed KhairieEVP, Head of U.S. CommercialTax withholding · $126K · 1,099 sh
Jul 15, 2026Form 4Tray ThomasPrincipal Accounting OfficerTax withholding · $126K · 1,098 sh
Jul 14, 2026Form 4Stein Steven HCMO & Head of Late-Stage Dev.Tax withholding · $2.5M · 21,830 sh · 10b5-1
Jul 14, 2026Form 4CAGNONI PABLO JPresident, Global Head of R&DTax withholding · $2.1M · 17,969 sh
Jul 14, 2026Form 4Tray ThomasPrincipal Accounting OfficerTax withholding · $79K · 692 sh
Jul 14, 2026Form 4Mayes Patrick AEVP & Chief Scientific OfficerTax withholding · $50K · 437 sh
Jul 2, 2026Form 4Meury WilliamChief Executive Officer · Director · PresidentTax withholding · $558K · 4,779 sh
Jul 2, 2026Form 4Stein Steven HCMO & Head of Late-Stage Dev.Tax withholding · $254K · 2,177 sh
Jul 2, 2026Form 4Tray ThomasPrincipal Accounting OfficerTax withholding · $56K · 477 sh
Jul 2, 2026Form 4Mayes Patrick AEVP & Chief Scientific OfficerTax withholding · $41K · 350 sh
Jun 30, 2026Form 4HARRIGAN EDMUNDDirectorAward · $29K · 255 sh
Jun 30, 2026Form 4Clancy Paul JDirectorAward · $29K · 252 sh
Jun 30, 2026Form 4BAKER BROS. ADVISORS LP, 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN6 filersAward · $0 · 800 sh
Jun 8, 2026Form 4BAKER BROS. ADVISORS LP, 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN6 filersAward · Non-Qualified Stock Option… · $0 · 12,222 sh
Jun 8, 2026Form 4HARRIGAN EDMUNDDirectorAward · Non Qualfied Stock Option … · $0 · 6,111 sh
Jun 8, 2026Form 4BRAWLEY OTIS WDirectorAward · Non Qualfied Stock Option … · $0 · 6,111 sh
Jun 8, 2026Form 4BIENAIME JEAN JACQUESDirectorAward · Non Qualfied Stock Option … · $0 · 6,111 sh
Jun 8, 2026Form 4FOUSE JACQUALYN ADirectorAward · Non Qualfied Stock Option … · $0 · 6,111 sh
Jun 8, 2026Form 4Clancy Paul JDirectorAward · Non Qualfied Stock Option … · $0 · 6,111 sh
Jun 8, 2026Form 4High Katherine ADirectorAward · Non Qualfied Stock Option … · $0 · 6,111 sh
Jun 8, 2026Form 4BAKER BROS. ADVISORS LP, 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN6 filersAward · $0 · 3,284 sh
Jun 8, 2026Form 4HARRIGAN EDMUNDDirectorAward · $0 · 1,642 sh
Jun 8, 2026Form 4BRAWLEY OTIS WDirectorAward · $0 · 1,642 sh
Jun 8, 2026Form 4BIENAIME JEAN JACQUESDirectorAward · $0 · 1,642 sh
Jun 8, 2026Form 4FOUSE JACQUALYN ADirectorAward · $0 · 1,642 sh
Jun 8, 2026Form 4Clancy Paul JDirectorAward · $0 · 1,642 sh
Jun 8, 2026Form 4High Katherine ADirectorAward · $0 · 1,642 sh
Jun 4, 2026Form 4Tray ThomasPrincipal Accounting OfficerExercise or conversion · $221K · 2,639 sh · 10b5-1
Jun 4, 2026Form 4Tray ThomasPrincipal Accounting OfficerExercise or conversion · Non-Qualified Stock Option… · $0 · 2,639 sh · 10b5-1
Jun 1, 2026Form 4CAGNONI PABLO JPresident, Global Head of R&DTax withholding · $2.4M · 25,469 sh
May 26, 2026Form 4BIENAIME JEAN JACQUESDirectorTax withholding · $1.3M · 13,059 sh · 10b5-1
May 26, 2026Form 4BIENAIME JEAN JACQUESDirectorExercise or conversion · $1.3M · 15,000 sh · 10b5-1
May 26, 2026Form 4BIENAIME JEAN JACQUESDirectorExercise or conversion · Non-Qualified Stock Option… · $0 · 15,000 sh · 10b5-1
May 19, 2026Form 4Clancy Paul JDirectorExercise or conversion · $1.3M · 15,000 sh · 10b5-1
May 19, 2026Form 4Clancy Paul JDirectorExercise or conversion · Non-Qualified Stock Option… · $0 · 15,000 sh · 10b5-1
May 8, 2026Form 4BAKER BROS. ADVISORS LP, 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN6 filersExercise or conversion · $2.5M · 30,000 sh
May 8, 2026Form 4BAKER BROS. ADVISORS LP, 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN6 filersExercise or conversion · Non-Qualified Stock Options · $0 · 30,000 sh
May 6, 2026Form 4Stein Steven HCMO & Head of Late-Stage Dev.Award · $0 · 44,124 sh
May 6, 2026Form 4CAGNONI PABLO JPresident, Global Head of R&DAward · $0 · 31,517 sh
May 4, 2026Form 4Upadhyay SuketuEVP & Chief Financial OfficerAward · Employee Stock Option (rig… · $0 · 38,429 sh
May 4, 2026Form 4Upadhyay SuketuEVP & Chief Financial OfficerAward · $0 · 26,343 sh
May 4, 2026Form 4Upadhyay SuketuEVP & Chief Financial OfficerAward · $0 · 13,171 sh
Apr 17, 2026Form 4CAGNONI PABLO JPresident, Global Head of R&DExercise or conversion · $1.3M · 18,667 sh · 10b5-1
Apr 17, 2026Form 4CAGNONI PABLO JPresident, Global Head of R&DExercise or conversion · Employee Stock Option (rig… · $0 · 18,667 sh · 10b5-1
Apr 15, 2026Form 4Meury WilliamChief Executive Officer · Director · PresidentExercise or conversion · $0 · 125,000 sh
Apr 15, 2026Form 4Stein Steven HCMO & Head of Late-Stage Dev.Award · $0 · 39,049 sh
Apr 15, 2026Form 4CAGNONI PABLO JPresident, Global Head of R&DAward · $0 · 27,892 sh
Mar 31, 2026Form 4HARRIGAN EDMUNDDirectorAward · $25K · 269 sh
Mar 31, 2026Form 4Clancy Paul JDirectorAward · $25K · 265 sh
Mar 31, 2026Form 4BAKER BROS. ADVISORS LP, 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN6 filersAward · $0 · 842 sh
Mar 25, 2026Form 4Trotta MatteoEVP, GM, Dermatology USTax withholding · $50K · 537 sh
Mar 17, 2026Form 4CAGNONI PABLO JPresident, R&DExercise or conversion · $1.2M · 18,667 sh · 10b5-1
Mar 17, 2026Form 4CAGNONI PABLO JPresident, R&DExercise or conversion · Employee Stock Option (rig… · $0 · 18,667 sh · 10b5-1
Feb 19, 2026Form 4CAGNONI PABLO JPresident, R&DExercise or conversion · $1.1M · 18,668 sh · 10b5-1
Feb 19, 2026Form 4CAGNONI PABLO JPresident, R&DExercise or conversion · Employee Stock Option (rig… · $0 · 18,668 sh · 10b5-1
Feb 2, 2026Form 4Morrissey Michael JamesEVP, Head of Tech. OperationsTax withholding · $19K · 185 sh
Feb 2, 2026Form 4Heeson LeeEVP, Head of Incyte IntlTax withholding · $11K · 111 sh
Jan 20, 2026Form 4Morrissey Michael JamesEVP, Head of Tech. OperationsTax withholding · $44K · 429 sh
Jan 16, 2026Form 4CAGNONI PABLO JPresident, R&DAward · Employee Stock Option (rig… · $0 · 28,475 sh
Jan 16, 2026Form 4Stein Steven HEVP & Chief Medical OfficerAward · Employee Stock Option (rig… · $0 · 19,932 sh
Jan 16, 2026Form 4Issa Mohamed KhairieEVP, Head of US OncologyAward · Employee Stock Option (rig… · $0 · 14,237 sh
Jan 16, 2026Form 4Heeson LeeEVP, Head of Incyte IntlAward · $0 · 8,911 sh
Jan 16, 2026Form 4Trotta MatteoEVP, GM, Dermatology USAward · Employee Stock Option (rig… · $0 · 8,542 sh
Jan 16, 2026Form 4Morrissey Michael JamesEVP, Head of Tech. OperationsAward · $0 · 7,426 sh
Jan 16, 2026Form 4Mayes Patrick AEVP & Chief Scientific OfficerAward · Employee Stock Option (rig… · $0 · 4,218 sh
Jan 16, 2026Form 4Tray ThomasPrincipal Accounting OfficerAward · Employee Stock Option (rig… · $0 · 2,425 sh
Jan 6, 2026Form 4Issa Mohamed KhairieEVP, Head of US OncologyTax withholding · $881K · 8,264 sh · 10b5-1
Dec 31, 2025Form 4Stein Steven HEVP & Chief Medical OfficerTax withholding · $1.3M · 13,292 sh
Dec 31, 2025Form 4Morrissey Michael JamesEVP, Head of Tech. OperationsTax withholding · $25K · 254 sh
Dec 31, 2025Form 4HARRIGAN EDMUNDDirectorAward · $24K · 245 sh
Dec 31, 2025Form 4Clancy Paul JDirectorAward · $24K · 241 sh
Dec 31, 2025Form 4BAKER BROS. ADVISORS LP, 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN6 filersAward · $0 · 656 sh

Reports and proxy statements#

Annual reports (10-K, 20-F, 40-F), quarterly reports (10-Q), current reports (8-K, 6-K) and proxy statements, newest first. An 8-K that furnishes a press release is headed by the release’s headline, its items beneath; any other 8-K is described by its items. A form opens the press release where there is one, else the document on EDGAR, or the filing’s index where it furnishes other exhibits.

2026 · 18 filings
FiledWhat it is
Aug 31, 20268-KOther events
Jul 28, 202610-QQuarterly report, Q2 2026 — revenue $1.67B (+38% y/y), net income $585.6M, EPS $2.81
Jul 28, 20268-KEarnings release — EPS $2.80 vs $1.76 est. (+59.1%); revenue $1.67B (+38% y/y) 9.3%
Jul 6, 20268-KIncyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology PortfolioOther events
Jun 22, 20268-KOther events
Jun 9, 20268-KShareholder vote results
Jun 8, 20268-KIncyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding DisordersOther events
May 27, 2026DEFA14AAdditional proxy materials
Apr 28, 2026ARSAnnual report to shareholders
Apr 28, 2026DEFA14AAdditional proxy materials
Apr 28, 2026DEF 14AProxy statement
Apr 28, 202610-QQuarterly report, Q1 2026 — revenue $1.27B (+21% y/y), net income $303.3M, EPS $1.47
Apr 28, 20268-KEarnings release — EPS $1.55 vs $1.14 est. (+36.0%); revenue $1.27B (+21% y/y) 2.1%
Mar 30, 20268-KDirectors or officers; compensation
Mar 26, 20268-KIncyte Announces Executive Leadership AppointmentsDirectors or officers; compensation
Mar 6, 20268-KOther events
Feb 10, 202610-KAnnual report, FY2025 — revenue $5.14B (+21% y/y), net income $1.29B, EPS $6.41
Feb 10, 20268-KEarnings release — EPS $1.56 vs $1.64 est. (−4.9%); revenue $1.51B (+28% y/y) 8.2%
2025 · 18 filings
FiledWhat it is
Dec 12, 20258-KDirectors or officers; compensation
Oct 28, 202510-QQuarterly report, Q3 2025 — revenue $1.37B (+20% y/y), net income $424.2M, EPS $2.11
Oct 28, 20258-KEarnings release — EPS $2.03 vs $1.38 est. (+47.1%); revenue $1.37B (+20% y/y) 1.5%
Oct 3, 20258-KDirectors or officers; compensation
Aug 7, 20258-KDirectors or officers; compensation
Jul 29, 202510-QQuarterly report, Q2 2025 — revenue $1.22B (+16% y/y), net income $405.0M, EPS $2.04
Jul 29, 20258-KEarnings release — EPS $1.31 vs $1.14 est. (+14.9%); revenue $1.22B (+16% y/y) 10.3%
Jun 27, 20258-KDirectors or officers; compensation
Jun 11, 20258-KDirectors or officers; compensation; Shareholder vote results
May 14, 20258-KOther events
Apr 29, 2025ARSAnnual report to shareholders
Apr 29, 2025DEFA14AAdditional proxy materials
Apr 29, 2025DEF 14AProxy statement
Apr 29, 202510-QQuarterly report, Q1 2025 — revenue $1.05B (+20% y/y), net income $158.2M, EPS $0.80
Apr 29, 20258-KEarnings release — EPS $0.89 vs $0.75 est. (+18.7%); revenue $1.05B (+20% y/y) 1.5%
Feb 10, 202510-KAnnual report, FY2024 — revenue $4.24B (+15% y/y), net income $32.6M, EPS $0.15
Feb 10, 20258-KEarnings release — EPS $1.09 vs $1.29 est. (−15.5%); revenue $1.18B (+16% y/y) 7.9%
Jan 10, 20258-KDirectors or officers; compensation
2024 · 16 filings
FiledWhat it is
Oct 29, 202410-QQuarterly report, Q3 2024 — revenue $1.14B (+24% y/y), net income $106.5M, EPS $0.54
Oct 29, 20248-KEarnings release — EPS $0.73 vs $0.88 est. (−17.1%); revenue $1.14B (+24% y/y) 12.0%
Jul 30, 202410-QQuarterly report, Q2 2024 — revenue $1.04B (+9% y/y), net income −$444.6M, EPS −$2.04
Jul 30, 20248-KEarnings release — EPS −$2.03 vs $0.59 est. (−444.1%); revenue $1.04B (+9% y/y) 1.2%
Jul 3, 20248-KMaterial definitive agreement; New financial obligation
Jun 14, 20248-KShareholder vote results
May 30, 2024DEFA14AAdditional proxy materials
May 13, 20248-KMaterial definitive agreement; Regulation FD disclosure
Apr 30, 202410-QQuarterly report, Q1 2024 — revenue $880.9M (+9% y/y), net income $169.5M, EPS $0.75
Apr 30, 20248-KEarnings release — EPS $0.38 vs $0.69 est. (−44.9%); revenue $880.9M (+9% y/y) 1.0%
Apr 29, 2024ARSAnnual report to shareholders
Apr 29, 2024DEFA14AAdditional proxy materials
Apr 29, 2024DEF 14AProxy statement
Feb 16, 202410-K/AAnnual report, amended
Feb 13, 202410-KAnnual report, FY2023 — revenue $3.70B (+9% y/y), net income $597.6M, EPS $2.65
Feb 13, 20248-KEarnings release — EPS $0.82 vs $1.04 est. (−21.1%); revenue $1.01B (+9% y/y) 2.6%
2023 · 15 filings — 7 × 8-K, 3 × 10-Q, 2 × DEFA14A and 3 other forms
FiledWhat it is
Oct 31, 202310-QQuarterly report, Q3 2023 — revenue $919.0M (+12% y/y), net income $171.3M, EPS $0.76
Aug 1, 202310-QQuarterly report, Q2 2023 — revenue $954.6M (+5% y/y), net income $203.5M, EPS $0.90
Jun 7, 2023DEFA14AAdditional proxy materials
May 2, 202310-QQuarterly report, Q1 2023 — revenue $808.7M (+10% y/y), net income $21.7M, EPS $0.10
Apr 28, 2023DEFA14AAdditional proxy materials
Apr 28, 2023ARSAnnual report to shareholders
Apr 28, 2023DEF 14AProxy statement
Feb 7, 202310-KAnnual report, FY2022 — revenue $3.39B (+14% y/y), net income $340.7M, EPS $1.52

7 current reports (8-K) not listed; the year is on EDGAR.

2022 · 14 filings — 8 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
FiledWhat it is
Nov 1, 202210-QQuarterly report, Q3 2022 — revenue $823.3M (+1% y/y), net income $112.8M, EPS $0.50
Aug 2, 202210-QQuarterly report, Q2 2022 — revenue $911.4M (+29% y/y), net income $161.4M, EPS $0.72
May 3, 202210-QQuarterly report, Q1 2022 — revenue $733.2M (+21% y/y), net income $38.0M, EPS $0.17
Apr 29, 2022DEFA14AAdditional proxy materials
Apr 29, 2022DEF 14AProxy statement
Feb 8, 202210-KAnnual report, FY2021 — revenue $2.99B (+12% y/y), net income $948.6M, EPS $4.27

8 current reports (8-K) not listed; the year is on EDGAR.

2021 · 16 filings — 9 × 8-K, 3 × 10-Q, 2 × DEFA14A and 2 other forms
FiledWhat it is
Nov 2, 202110-QQuarterly report, Q3 2021 — revenue $813.0M, net income $181.7M, EPS $0.82
Aug 3, 202110-QQuarterly report, Q2 2021 — revenue $705.7M (+3% y/y), net income $149.5M, EPS $0.67
May 14, 2021DEFA14AAdditional proxy materials
May 4, 202110-QQuarterly report, Q1 2021 — revenue $604.7M (+6% y/y), net income $53.5M, EPS $0.24
Apr 16, 2021DEFA14AAdditional proxy materials
Apr 16, 2021DEF 14AProxy statement
Feb 9, 202110-KAnnual report, FY2020 — revenue $2.67B (+24% y/y), net income −$295.7M, EPS −$1.36

9 current reports (8-K) not listed; the year is on EDGAR.

2020 · 16 filings — 9 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
FiledWhat it is
Nov 5, 202010-QQuarterly report
Aug 4, 202010-QQuarterly report, Q2 2020 — revenue $688.0M (+30% y/y), net income $290.3M, EPS $1.32
May 14, 2020DEFA14AAdditional proxy materials
May 5, 202010-QQuarterly report, Q1 2020 — revenue $568.5M (+14% y/y), net income −$720.6M, EPS −$3.33
Apr 24, 2020PX14A6GShareholder exempt solicitation
Apr 20, 2020DEF 14AProxy statement
Feb 13, 202010-KAnnual report, FY2019 — revenue $2.16B (+15% y/y), net income $446.9M, EPS $2.05

9 current reports (8-K) not listed; the year is on EDGAR.

2019 · 14 filings — 7 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
FiledWhat it is
Oct 29, 201910-QQuarterly report, Q3 2019 — revenue $551.6M (+23% y/y), net income $128.3M, EPS $0.59
Jul 30, 201910-QQuarterly report, Q2 2019 — revenue $529.9M (+2% y/y), net income $105.3M, EPS $0.48
Apr 30, 201910-QQuarterly report, Q1 2019 — revenue $497.9M (+30% y/y), net income $102.3M, EPS $0.47
Apr 22, 2019DEFA14AAdditional proxy materials
Apr 1, 2019PX14A6GShareholder exempt solicitation
Mar 21, 2019DEF 14AProxy statement
Feb 14, 201910-KAnnual report, FY2018 — revenue $1.88B (+23% y/y), net income $109.5M, EPS $0.51

7 current reports (8-K) not listed; the year is on EDGAR.

2018 · 13 filings — 8 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
FiledWhat it is
Oct 30, 201810-QQuarterly report, Q3 2018 — revenue $449.7M (+18% y/y), net income $29.2M, EPS $0.14
Jul 31, 201810-QQuarterly report, Q2 2018 — revenue $521.5M (+60% y/y), net income $52.4M, EPS $0.24
May 1, 201810-QQuarterly report, Q1 2018 — revenue $382.3M (−0% y/y), net income −$41.1M, EPS −$0.19
Mar 14, 2018DEF 14AProxy statement
Feb 15, 201810-KAnnual report, FY2017 — revenue $1.54B (+39% y/y), net income −$313.1M, EPS −$1.53

8 current reports (8-K) not listed; the year is on EDGAR.

2017 · 22 filings — 13 × 8-K, 3 × 10-Q, 2 × 10-K/A and 4 other forms
FiledWhat it is
Oct 31, 201710-QQuarterly report, Q3 2017 — revenue $381.5M (+42% y/y), net income $36.1M, EPS $0.17
Aug 1, 201710-QQuarterly report, Q2 2017 — revenue $326.4M (+33% y/y), net income −$12.5M, EPS −$0.06
Jun 30, 201710-K/AAnnual report, amended
May 4, 201710-QQuarterly report, Q1 2017 — revenue $384.1M (+46% y/y), net income −$187.1M, EPS −$0.96
Apr 17, 2017DEF 14AProxy statement
Mar 17, 201710-K/AAnnual report, amended
Feb 14, 201710-KAnnual report, FY2016 — revenue $1.11B (+47% y/y), net income $104.2M, EPS $0.54
Feb 14, 201710-Q/AQuarterly report, amended

14 current reports (8-K) not listed; the year is on EDGAR.

2016 · 21 filings — 14 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms

Counted, not listed; the year is on EDGAR.

2015 · 21 filings — 15 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms

Counted, not listed; the year is on EDGAR.

2014 · 16 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms

Counted, not listed; the year is on EDGAR.

2013 · 18 filings — 13 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form

Counted, not listed; the year is on EDGAR.

2012 · 16 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms

Counted, not listed; the year is on EDGAR.

2011 · 19 filings — 13 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms

Counted, not listed; the year is on EDGAR.

2010 · 17 filings — 11 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms

Counted, not listed; the year is on EDGAR.

2009 · 24 filings — 16 × 8-K, 3 × 10-Q, 2 × DEF 14A and 3 other forms

Counted, not listed; the year is on EDGAR.

2008 · 14 filings — 8 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms

Counted, not listed; the year is on EDGAR.

2007 · 13 filings — 8 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form

Counted, not listed; the year is on EDGAR.

2006 · 17 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms

Counted, not listed; the year is on EDGAR.

2005 · 15 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form

Counted, not listed; the year is on EDGAR.

2004 · 15 filings — 9 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms

Counted, not listed; the year is on EDGAR.

2003 · 10 filings — 5 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form

Counted, not listed; the year is on EDGAR.

2002 · 9 filings — 3 × 10-Q, 3 × 8-K, 1 × 10-K and 2 other forms

Counted, not listed; the year is on EDGAR.

2001 · 13 filings — 6 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms

Counted, not listed; the year is on EDGAR.

2000 · 18 filings — 12 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms

Counted, not listed; the year is on EDGAR.

1999 · 6 filings — 3 × 10-Q, 1 × 10-K, 1 × 8-K and 1 other form

Counted, not listed; the year is on EDGAR.

1998 · 15 filings — 6 × 8-K, 3 × 10-Q, 2 × 8-K/A and 4 other forms

Counted, not listed; the year is on EDGAR.

1997 · 6 filings — 3 × 10-Q, 1 × 10-K405, 1 × DEF 14A and 1 other form

Counted, not listed; the year is on EDGAR.

1996 · 4 filings — 3 × 10-Q, 1 × 8-K

Counted, not listed; the year is on EDGAR.

Insider, ownership and other filings#

Insider ownership (Forms 3, 4, 5 and 144), beneficial ownership (Schedules 13D and 13G), registration and prospectus (S-1, S-3, S-8, 424B and related) and the rest, counted by year, with the newest 25 of each of the latest 3 years shown. A Form 4 is one insider’s transaction report; a 13G is a passive holder above five percent.

2026 · 109 filings — 78 × 4, 23 × 144, 2 × 4/A and 4 other forms
FiledWhat it is
Oct 19, 20264Insider transaction (Form 4)
Oct 15, 2026144Notice of proposed sale (Form 144)
Oct 5, 20264Insider transaction (Form 4)
Oct 2, 20264Insider transaction (Form 4)
Oct 2, 20264Insider transaction (Form 4)
Oct 2, 20264Insider transaction (Form 4)
Sep 24, 20264Insider transaction (Form 4)
Sep 17, 20264Insider transaction (Form 4)
Sep 15, 2026144Notice of proposed sale (Form 144)
Aug 27, 20264Insider transaction (Form 4)
Aug 20, 20264Insider transaction (Form 4)
Aug 19, 2026144Notice of proposed sale (Form 144)
Aug 14, 20264Insider transaction (Form 4)
Aug 12, 2026144Notice of proposed sale (Form 144)
Aug 7, 20264Insider transaction (Form 4)
Aug 7, 20264Insider transaction (Form 4)
Aug 5, 2026144Notice of proposed sale (Form 144)
Aug 5, 2026144Notice of proposed sale (Form 144)
Aug 4, 20264Insider transaction (Form 4)
Aug 4, 20264Insider transaction (Form 4)
Aug 3, 2026144Notice of proposed sale (Form 144)
Jul 31, 2026144Notice of proposed sale (Form 144)
Jul 31, 2026144Notice of proposed sale (Form 144)
Jul 27, 20264Insider transaction (Form 4)
Jul 27, 20264Insider transaction (Form 4)

The newest 25 of 109 shown; the full year is on EDGAR.

2025 · 167 filings — 102 × 4, 52 × 144, 6 × 3 and 4 other forms
FiledWhat it is
Dec 22, 20254Insider transaction (Form 4)
Dec 19, 2025144Notice of proposed sale (Form 144)
Dec 19, 2025144Notice of proposed sale (Form 144)
Dec 18, 2025144Notice of proposed sale (Form 144)
Dec 18, 20254Insider transaction (Form 4)
Dec 17, 2025144Notice of proposed sale (Form 144)
Dec 16, 2025144Notice of proposed sale (Form 144)
Dec 16, 2025144Notice of proposed sale (Form 144)
Dec 15, 2025144Notice of proposed sale (Form 144)
Dec 12, 20254Insider transaction (Form 4)
Dec 11, 2025144Notice of proposed sale (Form 144)
Dec 10, 2025144Notice of proposed sale (Form 144)
Dec 10, 20254Insider transaction (Form 4)
Dec 10, 2025144Notice of proposed sale (Form 144)
Dec 3, 20254Insider transaction (Form 4)
Dec 3, 20254Insider transaction (Form 4)
Dec 3, 20254Insider transaction (Form 4)
Dec 3, 20253Initial insider holdings (Form 3)
Dec 2, 2025144Notice of proposed sale (Form 144)
Dec 1, 2025144Notice of proposed sale (Form 144)
Nov 25, 20254Insider transaction (Form 4)
Nov 24, 2025144Notice of proposed sale (Form 144)
Nov 21, 2025144Notice of proposed sale (Form 144)
Nov 19, 20254Insider transaction (Form 4)
Nov 17, 2025144Notice of proposed sale (Form 144)

The newest 25 of 167 shown; the full year is on EDGAR.

2024 · 109 filings — 77 × 4, 12 × 144, 4 × SC 13G and 7 other forms
FiledWhat it is
Dec 17, 20244Insider transaction (Form 4)
Dec 16, 2024144Notice of proposed sale (Form 144)
Dec 11, 20244Insider transaction (Form 4)
Dec 11, 20244Insider transaction (Form 4)
Dec 3, 20244Insider transaction (Form 4)
Nov 29, 2024144Notice of proposed sale (Form 144)
Nov 8, 2024SC 13GPassive holder above 5% (Schedule 13G)
Nov 8, 20244Insider transaction (Form 4)
Nov 6, 2024144Notice of proposed sale (Form 144)
Oct 21, 2024SC 13GPassive holder above 5% (Schedule 13G)
Oct 17, 2024SC 13GPassive holder above 5% (Schedule 13G)
Oct 4, 20244Insider transaction (Form 4)
Oct 3, 20244Insider transaction (Form 4)
Oct 3, 20243Initial insider holdings (Form 3)
Oct 2, 20244Insider transaction (Form 4)
Oct 2, 20244Insider transaction (Form 4)
Oct 2, 20244Insider transaction (Form 4)
Sep 16, 20244Insider transaction (Form 4)
Sep 16, 20244Insider transaction (Form 4)
Sep 13, 2024144Notice of proposed sale (Form 144)
Sep 12, 2024144Notice of proposed sale (Form 144)
Aug 14, 20244Insider transaction (Form 4)
Aug 12, 2024144Notice of proposed sale (Form 144)
Jul 29, 20244Insider transaction (Form 4)
Jul 25, 2024144Notice of proposed sale (Form 144)

The newest 25 of 109 shown; the full year is on EDGAR.

2023 · 86 filings — 70 × 4, 6 × SC 13G/A, 3 × 144 and 4 other forms

Counted, not listed; the year is on EDGAR.

2022 · 87 filings — 76 × 4, 5 × SC 13G/A, 2 × 3 and 3 other forms

Counted, not listed; the year is on EDGAR.

2021 · 106 filings — 96 × 4, 6 × SC 13G/A, 2 × SC 13D/A and 2 other forms

Counted, not listed; the year is on EDGAR.

2020 · 147 filings — 133 × 4, 5 × SC 13G/A, 2 × SEC STAFF LETTER and 6 other forms

Counted, not listed; the year is on EDGAR.

2019 · 132 filings — 111 × 4, 5 × 3, 5 × CT ORDER and 7 other forms

Counted, not listed; the year is on EDGAR.

2018 · 93 filings — 78 × 4, 5 × SC 13G/A, 2 × 3 and 6 other forms

Counted, not listed; the year is on EDGAR.

2017 · 114 filings — 96 × 4, 6 × SC 13G/A, 3 × CT ORDER and 6 other forms

Counted, not listed; the year is on EDGAR.

2016 · 75 filings — 58 × 4, 8 × SC 13G/A, 2 × 3 and 4 other forms

Counted, not listed; the year is on EDGAR.

2015 · 107 filings — 93 × 4, 4 × 3, 4 × SC 13G and 3 other forms

Counted, not listed; the year is on EDGAR.

2014 · 79 filings — 54 × 4, 6 × SC 13G/A, 5 × 3 and 7 other forms

Counted, not listed; the year is on EDGAR.

2013 · 52 filings — 37 × 4, 4 × 3, 4 × SC 13G/A and 5 other forms

Counted, not listed; the year is on EDGAR.

2012 · 55 filings — 37 × 4, 4 × 3, 4 × SC 13G/A and 5 other forms

Counted, not listed; the year is on EDGAR.

2011 · 61 filings — 45 × 4, 8 × SC 13G/A, 2 × S-8 and 5 other forms

Counted, not listed; the year is on EDGAR.

2010 · 65 filings — 47 × 4, 7 × SC 13G/A, 2 × CT ORDER and 6 other forms

Counted, not listed; the year is on EDGAR.

2009 · 63 filings — 32 × 4, 8 × SC 13G/A, 4 × SC 13D/A and 12 other forms

Counted, not listed; the year is on EDGAR.

2008 · 89 filings — 55 × 4, 7 × 4/A, 5 × SC 13G and 12 other forms

Counted, not listed; the year is on EDGAR.

2007 · 82 filings — 60 × 4, 8 × 424B7, 4 × SC 13G/A and 4 other forms

Counted, not listed; the year is on EDGAR.

2006 · 37 filings — 22 × 4, 3 × 3, 3 × SC 13G and 7 other forms

Counted, not listed; the year is on EDGAR.

2005 · 31 filings — 19 × 4, 4 × SC 13G, 4 × SC 13G/A and 4 other forms

Counted, not listed; the year is on EDGAR.

2004 · 82 filings — 53 × 4, 11 × 4/A, 4 × POS AM and 9 other forms

Counted, not listed; the year is on EDGAR.

2003 · 20 filings — 7 × 4, 4 × SC 13G/A, 3 × 3 and 4 other forms

Counted, not listed; the year is on EDGAR.

2002 · 11 filings — 5 × SC 13G/A, 3 × S-8, 1 × POS AM and 2 other forms

Counted, not listed; the year is on EDGAR.

2001 · 23 filings — 11 × 424B3, 4 × SC 13G/A, 3 × S-8 and 3 other forms

Counted, not listed; the year is on EDGAR.

2000 · 28 filings — 15 × 424B3, 4 × SC 13G/A, 3 × S-3/A and 3 other forms

Counted, not listed; the year is on EDGAR.

1999 · 8 filings — 3 × SC 13G/A, 1 × 424B3, 1 × POS AM and 3 other forms

Counted, not listed; the year is on EDGAR.

1998 · 13 filings — 4 × SC 13G/A, 3 × S-8, 2 × SC 13G and 4 other forms

Counted, not listed; the year is on EDGAR.

1997 · 8 filings — 2 × S-8, 2 × SC 13G/A, 1 × 424B4 and 3 other forms

Counted, not listed; the year is on EDGAR.

1996 · 5 filings — 2 × SC 13G, 1 × 424B4, 1 × S-3 and 1 other form

Counted, not listed; the year is on EDGAR.

1995 · 1 filing — 1 × SC 13G/A

Counted, not listed; the year is on EDGAR.

1994 · 2 filings — 1 × SC 13G, 1 × SC 13G/A

Counted, not listed; the year is on EDGAR.

About this data#

Incyte Corp. (INCY) has 2,616 filings on EDGAR going back to 1994: 35 annual reports, 94 quarterly reports and 278 current reports, plus proxy statements, insider forms and ownership schedules. Its latest annual report, a 10-K, was filed on Feb 10, 2026 for the fiscal year ended Dec 31, 2025. The most recent 8-K, on Aug 31, 2026, covered other events. Over the last 13 months insiders sold $28.6M in 20 sales and bought nothing on the open market; 121 other transactions (awards, exercises, tax withholding, gifts and plan purchases). Not investment advice.

Every row is a filing EDGAR lists for the registrants that have been Incyte Corp., read from the SEC’s submissions index each morning; a filing accepted after that read appears the next day. Where a company changed its filing entity (a holding-company reorganisation, Google into Alphabet) the predecessor’s filings are shown for the years it filed as the company, derived from the filings themselves. Dates are the filing date; the period is the report’s own. The latest 3 years of reports are listed in full, the next years to 10 without their 8-Ks, and older years are counted; the other forms are counted too, with the newest 25 of each of the latest 3 years shown. Insider transactions are the Form 4 and Form 5 documents themselves, filed since January 2026, every number as the insider filed it: a day’s lots are summed, a blank price adds its shares and no dollars, and a purchase through an employee stock plan is a plan purchase, not insider buying. An 8-K’s headline is the first line of the press release it furnishes (Exhibit 99), read from the filing and shown word for word; where two independent readings of the exhibit do not agree, the 8-K is described by its items instead. The documents stay on sec.gov, public domain, and every link opens the SEC’s copy. ChartRow does not summarise or interpret filings.

FAQ#

Where can I read INCY's latest 10-K?
INCY's latest annual report, a 10-K, was filed on Feb 10, 2026 for the fiscal year ended Dec 31, 2025. It is linked above and opens on EDGAR, the SEC's own site, where every exhibit is also listed.
When did INCY last file an 8-K?
On Aug 31, 2026 it covered other events. An 8-K reports a material event between quarterly reports; the one that furnishes the quarter's results is filed under Item 2.02, last on Jul 28, 2026.
Are INCY insiders buying or selling?
Over the last 13 months insiders sold $28.6M in 20 sales and bought nothing on the open market; 121 other transactions (awards, exercises, tax withholding, gifts and plan purchases). The most recent sale: CAGNONI PABLO J (President, Global Head of R&D) sold 2,642 shares on Oct 15, 2026 for $298K, under a 10b5-1 plan. Every figure is as the insider filed it on Form 4; a sale under a 10b5-1 plan was scheduled in advance.
How many SEC filings has INCY made?
2,616 filings are on EDGAR under the registrant records that have been Incyte Corp., going back to 1994; 1,713 of them are insider ownership forms (Forms 3, 4, 5 and 144).